A 2-arm, Prospective, Randomized, Controlled, Open-label, 12 Month Phase III Trial to Evaluate the Efficacy of Everolimus in Combination With a Centre Specific Standard Immunosuppressive Regimen Consisting of CNI, MPA and Steroids Versus a Standard Triple Immunosuppressive Regimen in Lung Transplant Recipients.

Trial Profile

A 2-arm, Prospective, Randomized, Controlled, Open-label, 12 Month Phase III Trial to Evaluate the Efficacy of Everolimus in Combination With a Centre Specific Standard Immunosuppressive Regimen Consisting of CNI, MPA and Steroids Versus a Standard Triple Immunosuppressive Regimen in Lung Transplant Recipients.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Everolimus (Primary) ; Ciclosporin; Corticosteroids; Mycophenolic acid; Tacrolimus
  • Indications Lung transplant rejection
  • Focus Pharmacodynamics
  • Acronyms 4EVERLUNG
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 05 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 02 Aug 2016 Planned End Date changed from 1 Feb 2019 to 1 Jan 2017.
    • 02 Aug 2016 Planned primary completion date changed from 1 Feb 2019 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top